Analyst Ratings For Avrobio Inc (NASDAQ:AVRO)
Today, Janney Montgomery Scott initiated coverage on Avrobio Inc (NASDAQ:AVRO) with a Buy.
There are 7 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Avrobio Inc (NASDAQ:AVRO) is Buy with a consensus target price of $35.40 per share, a potential 44.96% upside.
Some recent analyst ratings include
- 4/5/2019-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Buy rating
- 10/9/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Buy ➝ Buy rating
- 7/16/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Outperform rating and $40.00 price target
- 7/16/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Outperform rating
About Avrobio Inc (NASDAQ:AVRO)
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for Avrobio Inc (NASDAQ:AVRO)
Shares of Avrobio Inc closed the previous trading session at 24,42 +0,12 0,49 % with shares trading hands.
